Research Article
Year 2022,
Volume: 43 Issue: 4, 629 - 633, 27.12.2022
Abstract
Project Number
20111003
References
- [1] Baig S., Seevasant I., Mohamad J., Mukheem A., Huri H.Z., Kamarul T., Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?, Cell Death Dis., 7(1) (2016) 2058.
- [2] Narang A. S., & Desai D. S., Anticancer drug development, In Pharmaceutical perspectives of cancer therapeutics, New York, NY: Springer, (2009) 49-92.
- [3] Guo S., Song Y., He Y., Hu X. Y., and Wang L., Highly efficient artificial light-harvesting systems constructed in aqueous solution based on supramolecular self-assembly, Angew Chem. Int. Ed., 57 (2018) 3163–3167.
- [4] Yokoyama T., and Mizuguchi M., Crown ethers as transthyretin amyloidogenesis inhibitors, J. Med. Chem., 62 (2019) 2076–2082.
- [5] Zhang Y. M., Xu Q. Y., and Liu Y., Molecular recognition, and biological application of modified β-cyclodextrins, Sci. Chin., 62 (2019) 1–12.
- [6] Böhmer V., Calixarenes, macrocycles with (almost) unlimited possibilities, Angew. Chem. Int. Ed. Engl., 34 (2010) 713–745.
- [7] Bauer D., Andrae B., Gaß P., Trenz D., Becker S., and Kubik S., Functionalisable acyclic cucurbiturils, Org. Chem. Front., 6 (2019) 1555–1560.
- [8] Geraci C., Consoli G. M., Galante E., Bousquet E., Pappalardo M., and Spadaro A., Calix[4]arene decorated with four Tn antigenglycomimetic units and P3CS immunoadjuvant: synthesis, characterization, and anticancer immunological evaluation, Bioconjugate Chem., 19 (2008) 751–758.
- [9] Da Silva E., Lazar A. N., & Coleman A. W., Biopharmaceutical applications of calixarenes, Journal of Drug Delivery Science and Technology, 14(1) (2004) 3-20.
- [10] Yousaf A., Abd Hamid S., Bunnori N. M., & Ishola A. A., Applications of calixarenes in cancer chemotherapy: facts and perspectives, Drug design, development and therapy, 9 (2015) 2831.
- [11] Al-Hakimi A.N., Alminderej F., Aroua L., Alhag S.K., Alfaifi M.Y., Mahyoub, J.A., Eldin I., Elbehairi S., Alnafisah A.S., Design, synthesis, characterization of zirconium (IV), cadmium (II) and iron (III) complexes derived from Schiff base 2-aminomethylbenzimidazole, 2-hydroxynaphtadehyde and evaluation of their biological activity, Arab. J. Chem., 13 (2020) 7378–7389.
- [12] Maurya R.C., Chourasia J., Rajak D., Malik B.A., Mir J.M., Jain N., Batalia S., Oxovanadium(IV) complexes of bioinorganic and medicinal relevance: synthesis, characterization and 3D molecular modeling of some oxovanadium(IV) complexes involving O, N-donor environment of salicylaldehyde-based sulfa drug Schiff bases, Arab. J. Chem., 9 (2016) 1084-1100.
- [13] El-Saied F.A., Salem T.A., Shakdofa M.M.E., Al-Hakimi A.N., Radwan A.S., Antitumor activity of synthesized and characterized Cu (II), Ni (II) and Co (II) complexes of hydrazone-oxime ligands derived from 3-(hydroxyimino) butan-2-one, Beni-Suef Univ. J. basic Appl. Sci., 7 (2018) 420-429.
- [14] El-Saied F.A., Salem T.A., Shakdofa M.M.E., Al-Hakimi A.N., Anti-neurotoxic evaluation of synthetic and characterized metal complexes of thiosemicarbazone derivatives, Appl. Organomet. Chem., 32 (2018) 4215.
- [15] Gutsche C. D., and Iqbal M., p-ter-Butylcalix[4]arene, Org. Synth., 68 (1990a) 234-237.
- [16] Arnaud-Neu F., Collins E. M., Deasy M., Ferguson G., Harris S. J., Kaitner B., ... & Marques E., Synthesis, X-ray crystal structures, and cation-binding properties of alkyl calixaryl esters and ketones, a new family of macrocyclic molecular receptors, Journal of the American Chemical Society, 111(23) (1989) 8681-8691.
- [17] Narang A. S., & Desai D. S., Anticancer drug development, In Pharmaceutical perspectives of cancer therapeutics, New York, NY: Springer, (2009) 49-92.
- [18] Fang C., Tang S., Wang X., Sun X., Li H., Xu Y., Gu X., Xu J., Lasiokaurin derivatives: synthesis, antimicrobial and antitumor biological evaluation, and apoptosis-inducing effects, Arch Pharm. Res. (Seoul), 40 (2017) 796e806.
- [19] Mosmann T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, J. Immunol. Methods, 65 (1983) 55e63.
- [20] Karahan A., Yardan A., Yahsi Y., Kara H., Kurtaran R., N2O2 Tipi Schiff Bazı Ligandı ile Sentezlenen Cu(II) Kompleksinin X-Işını Yapısı ve Termal Özelliği, SDU Journal of Science (E-Journal), 8(2) (2013) 163-174.
- [21] Erdik E., , Organik Kimyada Spektroskopik Yöntemler, Fersa Matbaacılık San. Tic. Ltd. Şti., Ankara, (1993).
- [22] Balcı M., Nükleer Manyetik Rezonans Spektroskopisi, Gökçe Ofset Matbaacılık Ambalaj, Tur. Org. San. Ve Tic. Ltd. Şti., Ankara, (2000) 25-206.
Synthesis and Characterization of Novel Calix[4]arene Schiff Base Derivatives and Cytotoxicity Effect Evaluation on Cancer Cell Lines
Abstract
In this study, four stages were used to create brand-new p-tert-butyl-calix [4] arene Schiff base derivatives. First, p-tert-butyl-phenol and formaldehyde are reacted to create p-tert-butyl-calix [4] arene (1). In the following step, methyl bromoacetate and p-ter-butyl-calix [4] arene (1) were combined with acetone and reflux to create the p-tert-butyl-calix [4] arene diester complex (2). The third step involves reacting the diester compound (2) and hydrazine hydrate to create the p-tert-butyl-calix [4] arene hydrazinamide molecule (3). In the final stage, calix [4] arene Schiff base derivatives (4a-d) were produced in good yields by combining compound (3), p-tert-butyl-calix [4] arene hydrazinamide, and various aldehyde derivatives with reflux in EtOH. Through the use of 1H-NMR, 13C-NMR, infrared spectroscopy, and elemental analysis, the structures of produced compounds were verified. Four distinct cancer lines are linked to the antitumor activity of synthetic chemicals. (HT-29, a human colon cancer cell line, PC-3, a human prostate cancer cell line, C6, a rat glioma cell line and MCF-7, a human breast cancer cell line). Weak antitumor activity was seen in synthetic substances. However, only compound 4b was found to have potential efficacy against C6 and HT-29. It is clear that compound 4b, which has a nitro substitute on the phenyl ring, draws attention due to its increased activity.
Keywords
Supporting Institution
Selcuk University Scientific Research Projects Coordinatorship (BAP)
Project Number
20111003
References
- [1] Baig S., Seevasant I., Mohamad J., Mukheem A., Huri H.Z., Kamarul T., Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?, Cell Death Dis., 7(1) (2016) 2058.
- [2] Narang A. S., & Desai D. S., Anticancer drug development, In Pharmaceutical perspectives of cancer therapeutics, New York, NY: Springer, (2009) 49-92.
- [3] Guo S., Song Y., He Y., Hu X. Y., and Wang L., Highly efficient artificial light-harvesting systems constructed in aqueous solution based on supramolecular self-assembly, Angew Chem. Int. Ed., 57 (2018) 3163–3167.
- [4] Yokoyama T., and Mizuguchi M., Crown ethers as transthyretin amyloidogenesis inhibitors, J. Med. Chem., 62 (2019) 2076–2082.
- [5] Zhang Y. M., Xu Q. Y., and Liu Y., Molecular recognition, and biological application of modified β-cyclodextrins, Sci. Chin., 62 (2019) 1–12.
- [6] Böhmer V., Calixarenes, macrocycles with (almost) unlimited possibilities, Angew. Chem. Int. Ed. Engl., 34 (2010) 713–745.
- [7] Bauer D., Andrae B., Gaß P., Trenz D., Becker S., and Kubik S., Functionalisable acyclic cucurbiturils, Org. Chem. Front., 6 (2019) 1555–1560.
- [8] Geraci C., Consoli G. M., Galante E., Bousquet E., Pappalardo M., and Spadaro A., Calix[4]arene decorated with four Tn antigenglycomimetic units and P3CS immunoadjuvant: synthesis, characterization, and anticancer immunological evaluation, Bioconjugate Chem., 19 (2008) 751–758.
- [9] Da Silva E., Lazar A. N., & Coleman A. W., Biopharmaceutical applications of calixarenes, Journal of Drug Delivery Science and Technology, 14(1) (2004) 3-20.
- [10] Yousaf A., Abd Hamid S., Bunnori N. M., & Ishola A. A., Applications of calixarenes in cancer chemotherapy: facts and perspectives, Drug design, development and therapy, 9 (2015) 2831.
- [11] Al-Hakimi A.N., Alminderej F., Aroua L., Alhag S.K., Alfaifi M.Y., Mahyoub, J.A., Eldin I., Elbehairi S., Alnafisah A.S., Design, synthesis, characterization of zirconium (IV), cadmium (II) and iron (III) complexes derived from Schiff base 2-aminomethylbenzimidazole, 2-hydroxynaphtadehyde and evaluation of their biological activity, Arab. J. Chem., 13 (2020) 7378–7389.
- [12] Maurya R.C., Chourasia J., Rajak D., Malik B.A., Mir J.M., Jain N., Batalia S., Oxovanadium(IV) complexes of bioinorganic and medicinal relevance: synthesis, characterization and 3D molecular modeling of some oxovanadium(IV) complexes involving O, N-donor environment of salicylaldehyde-based sulfa drug Schiff bases, Arab. J. Chem., 9 (2016) 1084-1100.
- [13] El-Saied F.A., Salem T.A., Shakdofa M.M.E., Al-Hakimi A.N., Radwan A.S., Antitumor activity of synthesized and characterized Cu (II), Ni (II) and Co (II) complexes of hydrazone-oxime ligands derived from 3-(hydroxyimino) butan-2-one, Beni-Suef Univ. J. basic Appl. Sci., 7 (2018) 420-429.
- [14] El-Saied F.A., Salem T.A., Shakdofa M.M.E., Al-Hakimi A.N., Anti-neurotoxic evaluation of synthetic and characterized metal complexes of thiosemicarbazone derivatives, Appl. Organomet. Chem., 32 (2018) 4215.
- [15] Gutsche C. D., and Iqbal M., p-ter-Butylcalix[4]arene, Org. Synth., 68 (1990a) 234-237.
- [16] Arnaud-Neu F., Collins E. M., Deasy M., Ferguson G., Harris S. J., Kaitner B., ... & Marques E., Synthesis, X-ray crystal structures, and cation-binding properties of alkyl calixaryl esters and ketones, a new family of macrocyclic molecular receptors, Journal of the American Chemical Society, 111(23) (1989) 8681-8691.
- [17] Narang A. S., & Desai D. S., Anticancer drug development, In Pharmaceutical perspectives of cancer therapeutics, New York, NY: Springer, (2009) 49-92.
- [18] Fang C., Tang S., Wang X., Sun X., Li H., Xu Y., Gu X., Xu J., Lasiokaurin derivatives: synthesis, antimicrobial and antitumor biological evaluation, and apoptosis-inducing effects, Arch Pharm. Res. (Seoul), 40 (2017) 796e806.
- [19] Mosmann T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, J. Immunol. Methods, 65 (1983) 55e63.
- [20] Karahan A., Yardan A., Yahsi Y., Kara H., Kurtaran R., N2O2 Tipi Schiff Bazı Ligandı ile Sentezlenen Cu(II) Kompleksinin X-Işını Yapısı ve Termal Özelliği, SDU Journal of Science (E-Journal), 8(2) (2013) 163-174.
- [21] Erdik E., , Organik Kimyada Spektroskopik Yöntemler, Fersa Matbaacılık San. Tic. Ltd. Şti., Ankara, (1993).
- [22] Balcı M., Nükleer Manyetik Rezonans Spektroskopisi, Gökçe Ofset Matbaacılık Ambalaj, Tur. Org. San. Ve Tic. Ltd. Şti., Ankara, (2000) 25-206.
There are 22 citations in total.
Details
| Primary Language | English |
|---|---|
| Journal Section | Natural Sciences |
| Authors | |
| Project Number | 20111003 |
| Publication Date | December 27, 2022 |
| Submission Date | September 10, 2022 |
| Acceptance Date | December 10, 2022 |
| Published in Issue | Year 2022Volume: 43 Issue: 4 |
